Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility?

Pappas SG, Christians KK, Tolat PP, Mautz AP, Lal A, McElroy L, Gamblin TC, Turaga KK, Tsai S, Erickson B, Ritch P, Evans DB.

HPB (Oxford). 2014 Jan;16(1):70-4. doi: 10.1111/hpb.12074. Epub 2013 Mar 15.

2.

Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?

Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL.

J Thorac Oncol. 2014 Aug;9(8):1202-6. doi: 10.1097/JTO.0000000000000222.

3.

Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.

Heinrich S, Goerres GW, Schäfer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, Hany TF, von Schulthess GK, Clavien PA.

Ann Surg. 2005 Aug;242(2):235-43.

4.

The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.

Kim MJ, Lee KH, Lee KT, Lee JK, Ku BH, Oh CR, Heo JS, Choi SH, Choi DW.

Pancreas. 2012 Aug;41(6):897-903. doi: 10.1097/MPA.0b013e318252f4f5.

PMID:
22699202
5.

Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.

Yao J, Gan G, Farlow D, Laurence JM, Hollands M, Richardson A, Pleass HC, Lam VW.

ANZ J Surg. 2012 Mar;82(3):140-4. doi: 10.1111/j.1445-2197.2011.05972.x. Epub 2012 Jan 17.

PMID:
22510123
6.

PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.

Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, Eikman EA, Malafa M.

Ann Surg Oncol. 2008 Sep;15(9):2465-71. doi: 10.1245/s10434-008-9992-0. Epub 2008 Jun 13.

PMID:
18551347
7.

Positron emission tomography (PET) has limited utility in the staging of pancreatic adenocarcinoma.

Einersen P, Epelboym I, Winner MD, Leung D, Chabot JA, Allendorf JD.

J Gastrointest Surg. 2014 Aug;18(8):1441-4. doi: 10.1007/s11605-014-2529-x. Epub 2014 Jun 14.

PMID:
24928186
8.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
9.

Preoperative prediction of complete resection in pancreatic cancer.

Shah D, Fisher WE, Hodges SE, Wu MF, Hilsenbeck SG, Charles Brunicardi F.

J Surg Res. 2008 Jun 15;147(2):216-20. doi: 10.1016/j.jss.2008.02.061. Epub 2008 Mar 26.

PMID:
18498873
10.

Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.

Asagi A, Ohta K, Nasu J, Tanada M, Nadano S, Nishimura R, Teramoto N, Yamamoto K, Inoue T, Iguchi H.

Pancreas. 2013 Jan;42(1):11-9. doi: 10.1097/MPA.0b013e3182550d77.

11.
12.

The role of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer.

Crippa S, Salgarello M, Laiti S, Partelli S, Castelli P, Spinelli AE, Tamburrino D, Zamboni G, Falconi M.

Dig Liver Dis. 2014 Aug;46(8):744-9. doi: 10.1016/j.dld.2014.03.011. Epub 2014 Apr 8.

PMID:
24721105
13.

18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.

Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD.

Ann Surg. 1999 May;229(5):729-37; discussion 737-8. Review.

14.

Staging of pancreatic adenocarcinoma by imaging studies.

Wong JC, Lu DS.

Clin Gastroenterol Hepatol. 2008 Dec;6(12):1301-8. doi: 10.1016/j.cgh.2008.09.014. Epub 2008 Sep 27. Review.

PMID:
18948228
15.

¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases.

Nguyen VX, Nguyen CC, Nguyen BD.

JOP. 2011 Nov 9;12(6):557-66. Review.

16.

Evaluation of integrated positron emission tomography and computed tomography accuracy in detecting lymph node metastasis in patients with adenocarcinoma vs squamous cell carcinoma.

Billè A, Okiror L, Skanjeti A, Errico L, Arena V, Penna D, Ardissone F, Pelosi E.

Eur J Cardiothorac Surg. 2013 Mar;43(3):574-9. doi: 10.1093/ejcts/ezs366. Epub 2012 Jun 11.

PMID:
22689182
17.

EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma.

Mertz HR, Sechopoulos P, Delbeke D, Leach SD.

Gastrointest Endosc. 2000 Sep;52(3):367-71.

PMID:
10968852
18.

Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?

Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M.

Acta Gastroenterol Belg. 2007 Oct-Dec;70(4):331-8.

PMID:
18330088
19.

Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.

Wang XY, Yang F, Jin C, Fu DL.

World J Gastroenterol. 2014 Nov 14;20(42):15580-9. doi: 10.3748/wjg.v20.i42.15580. Review.

20.

PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer.

Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B, Mahipal A.

Clin Nucl Med. 2015 Nov;40(11):e501-5. doi: 10.1097/RLU.0000000000000837.

Supplemental Content

Support Center